Amarin

Amarin

SCHEMBL231815

CC(=O)OC(C)(C)/C=C/C(=O)[C@](C)(O)[C@H]1[C@H](O)C[C@@]2(C)[C@@H]3CC=C4[C@@H](C[C@H](O)C(=O)C4(C)C)[C@]3(C)C(=O)C[C@]12C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ITGAL P20701 3/20 1.00
NPC1 O15118 2/20 1.00
RAB9A P51151 2/20 1.00
IGF2BP1 Q9NZI8 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
HIF1A Q16665 2/20 1.00
LMNA P02545 1/20 1.00
MAPT P10636 1/20 1.00
STAT3 P40763 1/20 1.00
HTT P42858 1/20 1.00
ATM Q13315 1/20 1.00
KMT2A Q03164 1/20 0.63
PAX8 Q06710 2/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
ACHE P22303 2/20 0.58
CYP3A4 P08684 1/20 0.56
TYR P14679 1/20 0.39
PTPN1 P18031 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Amarin SCHEMBL22433345 1.00 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Cucurbitacin B SCHEMBL29602393 1.00 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL10013358 1.00 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL20121442 1.00 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL18177462 1.00 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL13668120 1.00 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL17531553 1.00 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL19186443 1.00 ITGAL (1.00) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Amarin SCHEMBL30863648 0.99 ITGAL (0.98) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2
Cucurbitacin E SCHEMBL29908892 0.92 ITGAL (0.84) ITGALNPC1RAB9AIGF2BP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1048 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122031598-A Preparation method and application of nephritis medicine 五源本草(山东)健康科技有限公司 2026-05-15 CN claimed
CN-122012585-A Application of CmBt and CmBr genes in regulating and controlling bitter taste of melon fruits 青岛农业大学 2026-05-12 CN claimed
US-20250325717-A1 ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-10-23 US claimed
US-20250313647-A1 MUTANT AND MISLOCALIZED CELL SURFACE NUCLEOPHOSMIN 1 AS A DIAGNOSTIC AND THERAPEUTIC TARGET OF HUMAN DISEASE THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-10-09 US claimed
EP-4603108-A1 HUMAN SERUM ALBUMIN BASED NANOCARRIERS FOR TARGETED IMMUNOTHERAPY Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2025-08-20 EP claimed
CN-119925642-A Nanostructure liposome and preparation method thereof 齐鲁理工学院 2025-05-06 CN claimed
US-12285488-B2 Oral dosage form containing theobromine-free cocoa LTS LOHMANN THERAPIE-SYSTEME AG (DE) 2025-04-29 US claimed
WO-2025073376-A1 MASKING PREPARATIONS AND COMPOUNDS FROM DAEMONOROPS DRACO (DRAGON BLOOD) SYMRISE AG (DE) 2025-04-10 WO claimed
CN-119707846-A Method for preparing cucurbitacin B derivative by strong acid dehydration and peroxy acid oxidation and application 常州大学 2025-03-28 CN claimed
CN-119677779-A Combination therapy with anti-nucleolin 1 antibodies and antibody conjugates 儿童医学中心公司 2025-03-21 CN claimed
CN-1883484-A Novel pharmacological use of cucurbitacine UNIV SHENYANG PHARMACEUTICAL (CN) 2006-12-27 CN claimed
US-20060246161-A1 METHOD OF MAKING MEDICAMENT FOR TREATING ANEMIA ULTRA BIOTECH LIMITED (GB) 2006-11-02 US claimed
CN-1698620-A Cucurbitacin emulsion capable of filtering out and eliminating bacteria and preparation method thereof UNIV SHENYANG PHARMACEUTICAL (CN) 2005-11-23 CN claimed
CN-1600316-A Drop Pills of cucurbitacin medication and preparation method BOERDA BIOTECH DEV CO LTD BEIJ (CN) 2005-03-30 CN claimed
CN-1513450-A Injection of compound pancreatic alcohol 周宝义 2004-07-21 CN claimed
US-20040138189-A1 Moderation of intracellular signals; antitumor agents; drug screening; administering cucurbitacin compound NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-07-15 US claimed
CN-1504191-A Cucurbitacin lipsome preparation method and formulation 沈阳药科大学 2004-06-16 CN claimed
CN-1405187-A Cucurbitacine cyclodextrin clathrate and preparation thereof SHENGYANG MEDICINE UNIV (CN) 2003-03-26 CN claimed
WO-2002078617-A2 MATERIALS AND METHODS FOR TREATMENT OF CANCER AND IDENTIFICATION OF ANTI-CANCER COMPOUNDS UNIVERSITY OF SOUTH FLORIDA (US) 2002-10-10 WO claimed
US-5925356-A Method of isolating cucurbitacin JP MORGAN CHASE BANK 1999-07-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060246161-A1 METHOD OF MAKING MEDICAMENT FOR TREATING ANEMIA HBG1, HBG2, HBZ ITGAL 1266/4885NPC1 4579/4885RAB9A 4595/4885
US-20040138189-A1 Moderation of intracellular signals; antitumor agents; drug screening; administering cucurbitacin compound STAT3, STAT1, JAK2 ITGAL 4681/4885NPC1 1707/4885RAB9A 2453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.